Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  New England Journal of Medicine

• Publication date

  2016-03-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1510926PMID 26933753PMCID PMC4900689
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.

  2016cited by this paper
• ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys1[S]

  2015cited by this paper
• Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.

  2014cited by this paper
• Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

  2014cited by this paper
• Loss-of-function mutations in APOC3, triglycerides, and coronary disease.

  2014cited by this paper
• Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks.

  2014cited by this paper
• Multiple rare alleles at LDLR and APOA5 confer risk for early-onset myocardial infarction

  2014cited by this paper
• Angptl4 serves as an endogenous inhibitor of intestinal lipid digestion.

  2014cited by this paper
• Triglycerides and cardiovascular disease.

  2014cited by this paper
• Common variants associated with plasma triglycerides and risk for coronary artery disease

  2013cited by this paper
• From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline

  2013cited by this paper
• Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization.

  2012cited by this paper
• A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff

  2012cited by this paper
• Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia[S]

  2012cited by this paper
• The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease

  2012cited by this paper
• Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

  2012cited by this paper
• GCTA: a tool for genome-wide complex trait analysis.

  2011cited by this paper
• S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in three prospective cohort studies

  2011cited by this paper
• Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.

  2011cited by this paper
• Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages.

  2010cited by this paper
• Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia.

  2010cited by this paper
• The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

  2010cited by this paper
• Lipoprotein lipase: from gene to obesity.

  2009cited by this paper
• A Highly Conserved Motif within the NH2-terminal Coiled-coil Domain of Angiopoietin-like Protein 4 Confers Its Inhibitory Effects on Lipoprotein Lipase by Disrupting the Enzyme Dimerization*

  2009cited by this paper
• Genetic Variation in ANGPTL4 Provides Insights into Protein Processing and Function

  2009cited by this paper
• S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies.

  2009cited by this paper
• Angptl 4 deficiency improves lipid metabolism, suppresses foam cell formation and protects against atherosclerosis.

  2009cited by this paper
• A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection

  2008cited by this paper
• ANGPTL4 E40K and T266M: Effects on Plasma Triglyceride and HDL Levels, Postprandial Responses, and CHD Risk

  2008cited by this paper
• Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data.

  2008cited by this paper
• Variation in ANGPTL4 and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study.

  2008cited by this paper
• Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans.

  2008cited by this paper
• Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL

  2007cited by this paper
• Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice

  2007cited by this paper
• Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue

  2006cited by this paper
• Lipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation

  2006cited by this paper
• Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism.

  2005cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase Published, JLR Papers in Press, September 16, 2002. DOI 10.1194/jlr.C200010-JLR200

  2002cited by this paper
• A solution to the problem of separation in logistic regression

  2002cited by this paper

• Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies

  2026cites this paper
• Non-remnant triglyceride-rich lipoproteins due to lipoprotein lipase deficiency increase atherosclerosis in mice

  2026cites this paper
• Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk.

  2026cites this paper
• Triglyceride-Rich Lipoproteins and Inflammation: Independent and Synergistic Roles in Cardiovascular Disease

  2026cites this paper
• Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings

  2025cites this paper
• Absence of the intracellular lipolytic inhibitor G0S2 enhances intravascular triglyceride clearance and abolishes diet-induced hypertriglyceridemia

  2025cites this paper
• The tear film protein profile in blepharitis

  2025cites this paper
• Genetics of remnant cholesterol.

  2025cites this paper
• Lipid-Lowering RNA Therapeutics for Atherosclerotic Cardiovascular Disease Prevention: A State−of−the−Art Review

  2025influential citation
• Gene therapy and genome editing for lipoprotein disorders

  2025cites this paper
• An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primates

  2025cites this paper
• Safely lowering triglycerides through ANGPTL4 inhibition.

  2025cites this paper
• Titin-Truncating variants predispose to dilated cardiomyopathy in populations genetically similar to african and european reference populations

  2025cites this paper
• Leveraging drug-target Mendelian randomization for tailored lipoprotein-lipid lowering

  2025cites this paper
• Combined analysis of bulk, single-cell RNA sequencing, and spatial transcriptomics reveals the expression patterns of lipid metabolism and ferroptosis in the immune microenvironment of metabolic-associated fatty liver disease.

  2025cites this paper
• Evaluating the Cardiometabolic Efficacy and Safety of Lipoprotein Lipase Pathway Targets in Combination with Approved Lipid-Lowering Targets: A Drug Target Mendelian Randomization Study

  2025cites this paper
• Antibody-Based Therapeutics for Hypercholesterolemia

  2025cites this paper
• Understanding the Role of Adipokines in Cardiometabolic Dysfunction: A Review of Current Knowledge

  2025cites this paper
• ANGPTL3/8 is an atypical unfoldase that regulates intravascular lipolysis by catalyzing unfolding of lipoprotein lipase

  2025cites this paper
• Time-Restricted Eating, ANGPTL4, and Reduction in Residual Cardiovascular Risk

  2025cites this paper
• Non-canonical splice variants in thoracic aortic dissection cases and Marfan syndrome with negative genetic testing

  2025cites this paper
• Pemafibrate Increases Circulating Angiopoietin-like Proteins 3 and 4 Without Promoting Pro-Atherogenic Changes in LDL and HDL Subspecies: A Post-Hoc Analysis of the PRESTIGE Study.

  2025cites this paper
• ANGPTL4 Prevents Atherosclerosis by Preserving KLF2 to Suppress EndMT and Mitigates Endothelial Dysfunction.

  2025cites this paper
• Metabolic reprogramming by endothelial ANGPTL4 depletion protects against diabetic kidney disease

  2025cites this paper
• Target Populations for Novel Triglyceride-Lowering Therapies.

  2025cites this paper
• Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.

  2025cites this paper
• Protein Drug Targets for Abdominal Aortic Aneurysm and Proteomic Associations Between Modifiable Risk Factors and Abdominal Aortic Aneurysm

  2025cites this paper
• Remnant cholesterol lowering in cardiovascular disease risk reduction in statin, ezetimibe, and PCSK9 inhibitor trials: meta-regression analyses.

  2025cites this paper
• Emerging Triglyceride-Rich Lipoprotein Targeted Therapies: An Unmet Need in Cardiometabolic Disease

  2025cites this paper
• Consensus document on the role of plasma triglycerides in cardiovascular disease from the Italian Society for the Study of Atherosclerosis (SISA).

  2025cites this paper
• Angiopoietin-like protein 4 dysregulation in kidney diseases: a promising biomarker and therapeutic target

  2025cites this paper
• Assessing long-term pleiotropic effects of potential novel triglyceride-lowering medications using variants identified by Mendelian randomization

  2025cites this paper
• RNA Inosine Sensor-Guided TadA Mutational Scanning for Toxicity Minimization of Adenine Base Editors.

  2025cites this paper
• Genetic determinants of lipid metabolism in cardioprotection: From mechanisms to clinical practice

  2025cites this paper
• Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia.

  2025cites this paper
• Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease.

  2025cites this paper
• Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization.

  2025cites this paper
• LILRB3 genetic variation is associated with kidney transplant failure in African American recipients

  2025cites this paper
• Angiopoietin-like 4 exacerbates renal tubular epithelial cell pyroptosis in acute kidney injury via integrin β5/FAK signaling pathway.

  2025cites this paper
• ANGPTL4: A Comprehensive Review of 25 Years of Research

  2025cites this paper
• Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent.

  2025cites this paper
• Polygenic Scoring for Detection of Ascending Thoracic Aortic Dilation

  2024cites this paper
• Single-cell transcriptomics reveal distinctive patterns of fibroblast activation in heart failure with preserved ejection fraction

  2024cites this paper
• ANGPTL4-the Link Binding Lipid Metabolism and Inflammation.

  2024cites this paper
• Macromolecular Interactions of Lipoprotein Lipase (LPL).

  2024cites this paper
• Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice

  2024cites this paper
• Impact of a post-lifestyle modification program in circulating angiopoietin-like proteins in Arab adolescents

  2024cites this paper
• Association of a genetic variant in angiopoietin‐like 3 with serum HDL‐C and risk of cardiovascular disease: A study of the MASHAD cohort over 6 years

  2024cites this paper
• Genome-First Approach to Rare and Common Variant Risk of Thoracic Aortic Aneurysm and Dissection

  2024cites this paper
• Targeted Knockdown of Hepatic Δ-5 Fatty Acid Desaturase FADS1 Aggravates Atherosclerosis in ApoE-/- Mice.

  2024cites this paper
• What Causes Premature Coronary Artery Disease?

  2024cites this paper
• Associations of Circulating ANGPTL3, C-Terminal Domain–Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality

  2024cites this paper
• Characterization of sexual dimorphism in ANGPTL4 levels and function

  2024cites this paper
• Myocardial Ischemia–Reperfusion Injury: Unraveling Pathophysiology, Clinical Manifestations, and Emerging Prevention Strategies

  2024cites this paper
• Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic multimorbidity

  2024cites this paper
• Establishment of a Mitochondrial Metabolism-Related Diagnostic Model in Schizophrenia Based on LASSO Algorithm

  2024cites this paper
• Relaxin suppresses atrial fibrillation, reverses fibrosis and reduces inflammation in aged hearts.

  2024cites this paper
• Angiopoietin-like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride-Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies

  2024cites this paper
• Plasma angiopoietin-like protein 4 as a novel biomarker predicting 10-year mortality in a community-based population: a longitudinal cohort study

  2024influential citation
• Impact of loss-of-function in angiopoietin-like 4 on the human phenome

  2024cites this paper
• Single-cell transcriptomic profiling of heart reveals ANGPTL4 linking fibroblasts and angiogenesis in heart failure with preserved ejection fraction

  2024cites this paper
• Personalized Drug Therapy: Innovative Concept Guided With Proteoformics

  2024cites this paper
• Remnant Cholesterol: Quantification, Concentrations by Sex and Age, and Risk of Ischemic Heart Disease.

  2024cites this paper
• Relation among hypertriglyceridaemia, cardiometabolic disease, and hereditary factors—design and rationale of the Stockholm hyperTRIglyceridaemia REGister study

  2024cites this paper
• Titin-Truncating variants Predispose to Dilated Cardiomyopathy in Diverse Populations

  2024cites this paper
• Hyperchylomicronemia causes endothelial cell inflammation and increases atherosclerosis

  2024cites this paper
• Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk

  2024influential citation
• The association between plasma angiopoietin-like protein 4, glucose and lipid metabolism during pregnancy, placental function, and risk of delivering large-for-gestational-age neonates.

  2024cites this paper
• SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes

  2024cites this paper
• Genetic polymorphisms of Leukocyte Immunoglobulin-Like Receptor B3 (LILRB3) gene in African American kidney transplant recipients are associated with post-transplant graft failure

  2024cites this paper
• Relationship between serum levels of ANGPTL8, Apo C2, and human placental lactogen (hPL) in patients with gestational diabetes mellitus: Interaction of LPL regulators with hPL, a possible contributing factor to insulin resistance.

  2024cites this paper
• Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets

  2024cites this paper
• Rare and common coding variants in lipid metabolism-related genes and their association with coronary artery disease

  2024influential citation
• Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention

  2024cites this paper
• Social Bonds Retain Oxytocin-Mediated Brain-Liver Axis to Retard Atherosclerosis

  2024cites this paper
• Correlation between the serum FABP4, ANGPTL3, and ANGPTL4 levels and coronary artery disease

  2024cites this paper
• The Emerging Potential of Apolipoprotein C-III Inhibition for ASCVD Prevention: A State-of-the-Art Review

  2024influential citation
• Obesity induces phenotypic switching of gastric smooth muscle cells through the activation of the PPARD/PDK4/ANGPTL4 pathway

  2024cites this paper
• Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease

  2024cites this paper
• Suppression of angiopoietin-like 4 reprograms endothelial cell metabolism and inhibits angiogenesis

  2023cites this paper
• Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia

  2023cites this paper
• Severe hypertriglyceridemia: Existing and emerging therapies.

  2023cites this paper
• The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease

  2023cites this paper
• The GPIHBP1-LPL complex and its role in plasma triglyceride metabolism: Insights into chylomicronemia.

  2023cites this paper
• Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors

  2023cites this paper
• Proteomic insights into the associations between obesity, lifestyle factors, and coronary artery disease

  2023cites this paper
• angptl4 gene expression as a marker of adaptive homeostatic response to social isolation across the lifespan in zebrafish.

  2023cites this paper
• Leukocyte–endothelial interaction in CKD

  2023cites this paper
• DNA and RNA Molecules as a Foundation of Therapy Strategies for Treatment of Cardiovascular Diseases

  2023cites this paper
• Dual role of ANGPTL4 in inflammation

  2023cites this paper
• Culprit lesion plaque characteristics and angiopoietin like 4 in acute coronary syndrome: A virtual histology-intravascular ultrasound analysis.

  2023cites this paper
• Genetics-based risk scores for prediction of premature coronary artery disease

  2023cites this paper
• High glucose-induced IL-7/IL-7R upregulation of dermal fibroblasts inhibits angiogenesis in a paracrine way in delayed diabetic wound healing

  2023cites this paper
• Single-cell transcriptomics reveal distinctive patterns of fibroblast activation in murine heart failure with preserved ejection fraction

  2023cites this paper
• Post-myocardial infarction treatment with resiniferatoxin modulates the expression of important genes involved in inflammation, plaque stability and angiogenesis

  2023cites this paper
• Integrated Control of Fatty Acid Metabolism in Heart Failure

  2023cites this paper
• Evaluation of Plasma Biomarkers for Causal Association With Peripheral Artery Disease

  2023cites this paper
• Angiopoietin-like proteins: cardiovascular biology and therapeutic targeting for the prevention of cardiovascular diseases.

  2023cites this paper
• ANGPTL3 negatively regulates IL-1β-induced NF-κB activation by inhibiting the IL1R1-associated signaling complex assembly

  2023cites this paper
• Phenome-wide Mendelian randomization study of plasma triglyceride levels and 2600 disease traits

  2023cites this paper